MedTrace Logo

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

NCT04524884 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-24

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.

Conditions

Interventions

DRUG

Surufatinib

Surufatinib is a tablet in the form of 50mg, oral, once a day.

DRUG

Toripalimab

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Qing-Hai Ji, MD · Fudan University

  • Yu-Long Wang, MD · Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-04-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524884 on ClinicalTrials.gov